Pre-made Vatelizumab benchmark antibody ( Whole mAb, anti-ITGA2 therapeutic antibody, Anti-BR/CD49B/GPIa/HPA-5/VLA-2/VLAA2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-615
Pre-Made Vatelizumab biosimilar, Whole mAb, Anti-ITGA2 Antibody: Anti-BR/CD49B/GPIa/HPA-5/VLA-2/VLAA2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vatelizumab is an immunomodulator. It binds to integrin alpha 2. It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Vatelizumab biosimilar, Whole mAb, Anti-ITGA2 Antibody: Anti-BR/CD49B/GPIa/HPA-5/VLA-2/VLAA2 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II/III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Chromos Molecular Systems;Glenmark Pharmaceuticals S.A.;Sanofi|
|Conditions Discontinued||Cancer;Chronic obstructive pulmonary disease;Multiple sclerosis;Retinal disorders;Rheumatoid arthritis;Ulcerative colitis|